ABCG2 and cancer: Moreover, ABCG2 has been implicated in conferring resistance to various chemotherapy drugs, including topotecan, SN-38, mitoxantrone, doxorubicin, and several tyrosine kinase inhibitors (TKIs) [71,72], contributing to multidrug resistance in cancer, as observed in colon cancer [73].